{"id":1521,"date":"2015-08-28T12:48:00","date_gmt":"2015-08-28T12:48:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/on-grindeks-financial-results-in-the-first-six-months-of-2015\/"},"modified":"2022-06-30T12:52:35","modified_gmt":"2022-06-30T12:52:35","slug":"on-grindeks-financial-results-in-the-first-six-months-of-2015","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/on-grindeks-financial-results-in-the-first-six-months-of-2015\/","title":{"rendered":"Par Grindeks rezult\u0101tiem 2015. gada pirmaj\u0101 pusgad\u0101"},"content":{"rendered":"\n<p>\u0160odien, 28. august\u0101 akciju sabiedr\u012bbas Grindeks \u201eNASDAQ Riga\u201d iesniegtie 2015. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2015. gada pirmaj\u0101 pusgad\u0101 bija 43,8 milj. euro, kas ir par 3,1 milj. euro vai par 8% vair\u0101k nek\u0101 2014. gada pirmaj\u0101 pusgad\u0101. Savuk\u0101rt, koncerna neto pe\u013c\u0146a, kas attiecin\u0101ma uz m\u0101tes sabiedr\u012bbas akcion\u0101riem, 2015. gada pirmaj\u0101 pusgad\u0101 bija 3,2 milj. euro, kas, sal\u012bdzinot ar 2014. gada pirmo pusgadu, ir palielin\u0101jusies par 0,4 milj. euro vai 14%. Bruto pe\u013c\u0146as rentabilit\u0101te 2015. gada pirmaj\u0101 pusgad\u0101 bija 45%, savuk\u0101rt t\u012br\u0101s pe\u013c\u0146as rentabilit\u0101te bija 7%. 2015. gada pirmaj\u0101 pusgad\u0101 Koncerna sara\u017eot\u0101produkcija eksport\u0113ta uz 55 pasaules valst\u012bm kopum\u0101 par 40,0 milj. euro, kas ir par 1,3 milj. eurovai par 4% vair\u0101k nek\u0101 2014. gada pirmaj\u0101 pusgad\u0101.<\/p>\n\n\n\n<p>Grindeks gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2015. gada pirmaj\u0101 pusgad\u0101 bija 39,4 milj.&nbsp;<em>euro<\/em>&nbsp;un ir palielin\u0101jies, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, par 4,9 milj.&nbsp;<em>euro<\/em>&nbsp;vai 14%. P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2015. gada pirmaj\u0101 pusgad\u0101 sasniedza 23,6 milj.&nbsp;<em>euro<\/em>, kas ir par 5,3 milj.&nbsp;<em>euro<\/em>&nbsp;vai 18% maz\u0101k nek\u0101 2014. gada pirmaj\u0101 pusgad\u0101. Sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, iev\u0113rojam\u0101kais p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Arm\u0113nij\u0101 par 18%, Gruzij\u0101 par 27%, Kirgizst\u0101n\u0101 par 28% un Turkmenist\u0101n\u0101 par 26%.&nbsp;2015. gada pirmaj\u0101 pusgad\u0101 Grindeks ir papildin\u0101jis produktu kl\u0101stu un&nbsp;ieviesis UDHS (ursodeoxycholic acid, ursodeoksiholsk\u0101be) gatavo z\u0101\u013cu formu (kapsulu), k\u0101 ar\u012b uzs\u0101cis \u0161\u012b produkta ra\u017eo\u0161anu un eksportu uz div\u0101m valst\u012bm \u2013 Krieviju un Gruziju. T\u0101d\u0113j\u0101di Grindeks ir papla\u0161in\u0101jis savu pied\u0101v\u0101jumu gastroenter\u0101l\u0101 trakta un vielmai\u0146as z\u0101\u013cu terapeitiskaj\u0101 grup\u0101.<\/p>\n\n\n\n<p>Pateicoties sekm\u012bgai biznesa diversifik\u0101cijai un darb\u012bbas att\u012bst\u012bbai jaunos tirgos, p\u0101rdo\u0161anas apjoms Baltijas un cit\u0101s valst\u012bs sasniedza 15,9 milj.&nbsp;<em>euro<\/em>, kas ir par 10,2 milj.&nbsp;<em>euro<\/em>&nbsp;vai 2,8 reizes vair\u0101k k\u0101 2014. gada pirmaj\u0101 pusgad\u0101. P\u0101rdo\u0161anas apjoms Polij\u0101, sal\u012bdzinot ar 2014. gada pirmo pusgadu ir palielin\u0101jies 6,4 reizes, savuk\u0101rt Vjetnam\u0101 \u2013 2,6 reizes. P\u0101rdo\u0161anas apjoms Latvij\u0101 \u0161\u012b gada pirmaj\u0101 pusgad\u0101 sasniedza 3,1 milj.&nbsp;<em>euro<\/em>, kas, sal\u012bdzinot ar iepriek\u0161\u0113j\u0101 gada pirmo pusgadu, palielin\u0101jies par 1,3 milj.&nbsp;<em>euro<\/em>&nbsp;vai 72%.<\/p>\n\n\n\n<p>2015.gada pirmaj\u0101 pusgad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 4,1 milj.<em>euro<\/em>, kas ir par 2,0 milj.&nbsp;<em>euro&nbsp;<\/em>vai 33% maz\u0101k nek\u0101&nbsp;2014. gada pirmaj\u0101 pusgad\u0101. Galvenie Grindeks akt\u012bvo farmaceitisko vielu eksporta tirgi ir&nbsp;ES valstis,&nbsp;ASV, Kan\u0101da un Jap\u0101na. Grindeks piepras\u012bt\u0101k\u0101s akt\u012bv\u0101s farmaceitisk\u0101s vielas 2015. gada pirmaj\u0101 pusgad\u0101 ir oksitoc\u012bns, zopiklons, ksilaz\u012bns, medetomid\u012bns un pimobend\u0101ns.<\/p>\n\n\n\n<p>AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Juris Bundulis: \u201eNotikumi un izmai\u0146as glob\u0101laj\u0101 ekonomik\u0101 sp\u0113c\u012bgi ietekm\u0113 Latvijas eksport\u0113t\u0101jus, ar\u012b akciju sabiedr\u012bbu Grindeks. Soli pa solim m\u016bsu \u012bstenot\u0101 uz\u0146\u0113muma biznesa diversifik\u0101cija nes pozit\u012bvus rezult\u0101tus, t\u0101p\u0113c esmu gandar\u012bts par Grindeks sasniegumiem Vjetnam\u0101, Polij\u0101 un cit\u0101s valst\u012bs \u0101rpus tradicion\u0101lajiem uz\u0146\u0113muma tirgiem. Ap\u0146\u0113m\u012bbas pilni m\u0113s turpin\u0101sim invest\u0113t jaunu tirgu att\u012bst\u012bb\u0101. Neskatoties uz to, m\u0113s ar\u012b turpm\u0101k lielu uzman\u012bbu velt\u012bsim NVS valst\u012bm \u2013 gan lai mazin\u0101tu savus biznesa riskus, gan lai pilnveidotu darb\u012bbu.\u201d<\/p>\n\n\n\n<p><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_finansu_parskats_2015_Q2.pdf\" target=\"_blank\" rel=\"noopener\"><\/a><a href=\"https:\/\/grindeks.lv\/wp-content\/uploads\/2016\/12\/Grindeks_finansu_parskats_2015_Q2.pdf\" target=\"_blank\" rel=\"noopener\">Grindeks 2015. gada 1. pusgada nerevid\u0113ti finan\u0161u p\u0101rskati (453 KB)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u0160odien, 28. august\u0101 akciju sabiedr\u012bbas Grindeks \u201eNASDAQ Riga\u201d iesniegtie 2015. gada pirm\u0101 pusgada nerevid\u0113tie konsolid\u0113tie finan\u0161u p\u0101rskati liecina, ka Koncerna apgroz\u012bjums 2015. gada pirmaj\u0101 pusgad\u0101&#8230;<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=1521"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/1521\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=1521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=1521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=1521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}